Institute for Physiology and Pathophysiology, University of Marburg, Marburg, Germany.
Nat Chem Biol. 2013 Aug;9(8):507-13. doi: 10.1038/nchembio.1271. Epub 2013 Jun 2.
Most known small-molecule inhibitors of voltage-gated ion channels have poor subtype specificity because they interact with a highly conserved binding site in the central cavity. Using alanine-scanning mutagenesis, electrophysiological recordings and molecular modeling, we have identified a new drug-binding site in Kv1.x channels. We report that Psora-4 can discriminate between related Kv channel subtypes because, in addition to binding the central pore cavity, it binds a second, less conserved site located in side pockets formed by the backsides of S5 and S6, the S4-S5 linker, part of the voltage sensor and the pore helix. Simultaneous drug occupation of both binding sites results in an extremely stable nonconducting state that confers high affinity, cooperativity, use-dependence and selectivity to Psora-4 inhibition of Kv1.x channels. This new mechanism of inhibition represents a molecular basis for the development of a new class of allosteric and selective voltage-gated channel inhibitors.
大多数已知的电压门控离子通道小分子抑制剂对亚型的特异性较差,因为它们与中央腔中高度保守的结合位点相互作用。我们使用丙氨酸扫描突变、电生理记录和分子建模,在 Kv1.x 通道中鉴定出一个新的药物结合位点。我们报告说 Psora-4 可以区分相关的 Kv 通道亚型,因为除了结合中央孔腔之外,它还结合位于由 S5 和 S6 的背面、S4-S5 接头、部分电压传感器和孔螺旋形成的侧袋中的第二个不太保守的位点。两种结合位点的药物同时占据会导致非常稳定的非传导状态,从而赋予 Psora-4 对 Kv1.x 通道的高亲和力、协同性、使用依赖性和选择性抑制作用。这种新的抑制机制代表了开发新型变构和选择性电压门控通道抑制剂的分子基础。